Treatment of Lobular Capillary Hemangioma with the Nd:YAG Laser: Retrospective Case Series of 25 Patients

Bédard, Marie-Sophie; Boulanger, J. C.

doi:10.2310/7750.2008.08053

Cited by 11 publications

(10 citation statements)

References 5 publications

(5 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Overtreatment may often results in dyspigmentation. Nd:YAG laser (1064 nm) is a viable option for resistant or difficult‐to‐treat lesions . One of the vascular devices on the market has a first pulse with highly absorbable 595 nm laser followed millisecond later by the deeper penetrating 1064 nm laser.…”

Section: Treatment Of Different Vascular Lesionsmentioning

confidence: 99%

“…Recommendation We recommend early intervention when an IH is diagnosed as a haemangioma that will cause problems. First choices are LPDL (595 nm) or millisecond Nd:YAG(1064 nm) lasers with cooling (GRADE 1B) . As a second choice, alexandrite (755 nm) or KTP (532 nm; for superficial lesions) lasers may be used (GRADE 1C) …”

Section: Treatment Of Different Vascular Lesionsmentioning

confidence: 99%

See 1 more Smart Citation

Guidelines of care for vascular lasers and intense pulse light sources from the European Society for Laser Dermatology

Adamič¹,

Pavlović

Rubin

et al. 2015

Acad Dermatol Venereol

View full text Add to dashboard Cite

Aim Lasers and non-coherent intense pulse light sources (IPLS) are based on the principle of selective photothermolysis and can be used for the treatment of many vascular skin lesions. A variety of lasers has been developed for the treatment of congenital and acquired vascular lesions which incorporate these concepts into their design. Although laser and light sources are very popular due to their non-invasive nature, caution should be considered by practitioners and patients to avoid permanent side-effects. The aim of these guidelines is to give evidence-based recommendations for the use of lasers and IPLS in the treatment of vascular lesions. Results Lasers and IPLS are very useful and sometimes the only available method to treat various vascular lesions. It is of a paramount importance that the type of laser or IPLS and their specific parameters are adapted to the indication but also that the treating physician is familiar with the device to be used. The crucial issue in treating vascular lesions is to recognize the immediate end-point after laser treatment. This is the single most important factor to ensure both the efficacy of the treatment and avoidance of serious side-effects. Methods Conflicts of interestNone declared. Funding sourceNone.Since the publication of previous European Society of Laser Dermatology (ESLD) guidelines in 2007, there have been significant advances in the field of laser treatment of common vascular lesions.1 These guidelines have been updated by the Consensus Panel under the auspices of the ESLD. Methodology, search strategy and recommendation formulation are described in Appendix II. A brief overview of vascular lasersStandard vascular lasers include pulsed dye lasers (585 and 595 nm), and KTP-lasers (532 nm), followed by longer wavelength lasers such as alexandrite lasers (755 nm), diode lasers (800-900 nm) and millisecond Nd:YAG lasers (1064 nm). New developments include a non-uniform pulse sequence or a dual-wavelength modality (combined dual wavelength 595 and 1064 nm-pulsed dye and Nd:YAG laser) and microsecond Nd: YAG lasers. [2][3][4][5][6] Even fractional photothermolysis has begun to be used for selected vascular lesions. Lasers' and intense pulse light sources (IPLS) effects are based on the principle of selective photothermolysis. In general, they deliver a precisely graded aliquot of energy to a defined area of the skin in a reproducible, standardized manner that almost always involves addition or evacuation of heat. The greatestThe first two authors have contributed equally to the manuscript.

show abstract

Section: Treatment Of Different Vascular Lesionsmentioning

confidence: 99%

Section: Treatment Of Different Vascular Lesionsmentioning

confidence: 99%

Guidelines of care for vascular lasers and intense pulse light sources from the European Society for Laser Dermatology

Adamič¹,

Pavlović

Rubin

et al. 2015

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…CHs can be successfully treated with various methods such as cryotherapy, yttrium aluminium garnet (YAG) laser, topical or intralesional steroids or neoplastic agents (vincristine), oral propranolol, and surgical excision. However, these treatments are mostly used for cutaneous, oral, and subglottic hemangiomas [8,9]. Although case reports are limited in number, successful results with different bronchoscopic techniques were obtained in the treatment of tracheal CHs.…”

Section: Discussionmentioning

confidence: 99%

A Rare Cause of Hemoptysis in Childhood: Tracheal Capillary Hemangioma

et al. 2017

View full text Add to dashboard Cite

A Rare Cause of Hemoptysis in Childhood: Tracheal Capillary HemangiomaHemangiomas are benign tumors most frequently seen in childhood and are mostly associated with cutaneous and mucosal surfaces. Tracheal capillary hemangiomas are extremely rare. The most common presenting symptom is hemoptysis, ranging from minor to major and chronic cough. We present the case of a 12-year-old boy with recurrent hemoptysis due to tracheal capillary hemangioma, who was treated with interventional bronchoscopy. KEYWORDS: Hemoptysis, capillary hemangioma, trachea INTRODUCTIONPrimary tumors of the trachea are extremely rare, with an estimated incidence of approximately 2.7 new cases per million per year, and usually malignant in adults [1]. Lobular capillary hemangioma (LCH) is a benign tumor, more commonly seen in children, with a distinctive lobular arrangement of capillaries in edematous and fibroblastic stroma [2]. The usual sites of tumor are the lips, nose, oral cavity, and tongue. It typically presents with nonspecific clinical symptoms, such as cough and hemoptysis. Stridor is observed with subglottic localization of the tumor. Radiologic studies and bronchoscopy are usually sufficient for diagnosis. Interventional bronchoscopic techniques can treat these lesions and avoid aggressive surgical approaches. Mills et al. [3] reviewed 639 cases of vascular lesions of the oral cavity and upper respiratory tract. They found only 73 cases with LCH and no case with localization in or below the larynx. There is very limited literature on tracheal LCH [1]. We present here the diagnosis and management of a rare case of tracheal LCH that was successfully treated with interventional bronchoscopy. CASE PRESENTATIONA 12-year-old boy was admitted to our clinic due to recurrent hemoptysis. His symptoms started 2 years ago with approximately 100 mL of hemorrhage in a day after coughing. He also mentioned that a small amount of hemoptysis recurred whenever he had a respiratory tract infection. There was nothing in his history to indicate causes of hemoptysis, such as tuberculosis, recurrent lower respiratory tract infections, intravenous or oral drug use, or antibiotic therapy. He had no pets. Physical examination showed no abnormalities. His hematologic parameters were as follows: activated partial thromboplastin time: 24.7 sc; prothrombin time:15.2 s-58.2%, INR: 1.22; within normal limits). Other chemical laboratory test results were normal, as were chest radiography findings (Figure 1). Sputum acid-fast bacilli and Löwenstein-Jensen cultures were negative. Thorax computed tomography showed a polypoid lesion on the left lateral wall of the proximal trachea (Figure 2). Rigid bronchoscopy revealed a reddish polypoid lesion with a smooth surface on the left lateral wall localized in the proximal one-third of the trachea. The lesion was attached to the tracheal wall with a short pedicle (Figure 3a). The lesion was excised with electrocautery snare and was taken using biopsy forceps. The tracheal wall was coagulated with argon plasma coagulation...

show abstract

“…These defects are treated with various approaches; surgical intervention is sometimes required [13]. Lobular capillary hemangiomas have been successfully treated with various other methods involving cryotherapy, YAG laser therapy [14], topical or intralesional steroids or neoplastic agents, propranolol (in children), and surgical excision [15]. If bleeding is a potential risk, such as it is with vascular tumors, having interventional bronchoscopy (e.g., rigid bronchoscopy) available during the removal would be highly suggested.…”

Section: Discussionmentioning

confidence: 99%

Lobular Capillary Hemangioma in the Posterior Trachea: A Rare Cause of Hemoptysis

Amy

Enrique

2012

Case Reports in Pulmonology

View full text Add to dashboard Cite

Lobular capillary hemangiomas (LCH) have been cited in the literature as a rare potential cause for recurrent hemoptysis. They are mostly associated with cutaneous and mucosal surfaces. Rarely do they affect the trachea and associated airways in adults. Lobular capillary hemangiomas can be associated with previous trauma to the airway; however, drugs, hormonal shifts, viral oncogenes, production of angiogenic factors, and cytogenetic clonal deletion abnormalities can also influence these lesions. We document a case of a posterior wall tracheal hemangioma with associated recurrent hemoptysis in a 22-year-old male on testosterone therapy. An LCH attached to the posterior tracheal wall can be technically difficult to remove due to risk of perforation and bleeding. There have been no cases documented of posterior wall LCH.

show abstract

Treatment of Lobular Capillary Hemangioma with the Nd:YAG Laser: Retrospective Case Series of 25 Patients

Cited by 11 publications

References 5 publications

Guidelines of care for vascular lasers and intense pulse light sources from the European Society for Laser Dermatology

Guidelines of care for vascular lasers and intense pulse light sources from the European Society for Laser Dermatology

A Rare Cause of Hemoptysis in Childhood: Tracheal Capillary Hemangioma

Lobular Capillary Hemangioma in the Posterior Trachea: A Rare Cause of Hemoptysis

Contact Info

Product

Resources

About